HomeComparePROCF vs CHD

PROCF vs CHD: Dividend Comparison 2026

PROCF yields 1818.18% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROCF wins by $4103414683.81M in total portfolio value
10 years
PROCF
PROCF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PROCF calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — PROCF vs CHD

📍 PROCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROCFCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROCF + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROCF pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROCF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, PROCF beats the other by $3,147,377,270,441,847.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROCF + CHD for your $10,000?

PROCF: 50%CHD: 50%
100% CHD50/50100% PROCF
Portfolio after 10yr
$2051707341.93M
Annual income
$1,851,398,394,378,849.80/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

PROCF
No analyst data
Altman Z
0.4
Piotroski
6/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROCF buys
0
CHD buys
0
No recent congressional trades found for PROCF or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROCFCHD
Forward yield1818.18%1.27%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$4103414683.84M$26.4K
Annual income after 10y$3,702,796,788,756,407.00$1,292.51
Total dividends collected$4074760433.31M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PROCF vs CHD ($10,000, DRIP)

YearPROCF PortfolioPROCF Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$192,518$181,818.18$10,856$156.32+$181.7KPROCF
2$3,477,331$3,271,336.99$11,811$195.24+$3.47MPROCF
3$58,943,217$55,222,471.89$12,883$244.38+$58.93MPROCF
4$937,891,469$874,822,227.57$14,091$306.64+$937.88MPROCF
5$14,012,869,532$13,009,325,660.38$15,463$385.88+$14012.85MPROCF
6$196,647,994,247$181,654,223,846.76$17,033$487.17+$196647.98MPROCF
7$2,592,865,386,485$2,382,452,032,641.56$18,843$617.36+$2592865.37MPROCF
8$32,132,661,421,271$29,358,295,457,731.54$20,947$785.72+$32132661.40MPROCF
9$374,409,247,740,494$340,027,300,019,734.44$23,419$1,004.91+$374409247.72MPROCF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$26,350$1,292.51+$4103414683.81MPROCF

PROCF vs CHD: Complete Analysis 2026

PROCFStock

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Full PROCF Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this PROCF vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROCF vs SCHDPROCF vs JEPIPROCF vs OPROCF vs KOPROCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.